IVD Studies Using Leftover Blood Samples Must Have Informed Consent - FDA
This article was originally published in The Gray Sheet
Executive SummaryManufacturers of in vitro diagnostics will have to obtain informed consent from patients whose leftover blood samples are used in clinical trials or risk jeopardizing their regulatory submissions, according to FDA officials.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.